Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q1- Text added to 2021 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AHFCA, antagonist, atrial, bendamustine, BRCA, called, Catalogue, categorical, chromosome, comment, conditionally, Crack, deadline, deletion, dexamethasone, dMMR, ESCC, esophageal, exhibit, extraterritorial, fibrillation, flutter, fundraising, gBRCA, headquartered, immunomodulatory, Intensifying, intolerant, iPSC, median, microsatellite, mismatch, MZL, NK, overarching, PDUFA, PFS, plainly, preapproval, processor, proteasome, recurrent, Registrar, rituximab, safest, secondary, seemingly, SEQUOIA, Shoreline, solution, survival, TN, top, topline, VIE
Removed:
accessing, AMG, BioAtla, bipartisan, Macao, pilot
Valuein 2021 Q1 filing- Value in 2021 Q2 filing
Original filings
Filing view